Boesgaard T W, Castella S I, Andersen G, Albrechtsen A, Sparsø T, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O
Steno Diabetes Center, Copenhagen, Denmark.
Diabet Med. 2007 Jul;24(7):702-6. doi: 10.1111/j.1464-5491.2007.02110.x. Epub 2007 Apr 24.
The glutamate decarboxylase gene (GAD2) encodes GAD65, an enzyme catalysing the production of the gamma-aminobutyric acid (GABA) which interacts with neuropeptide Y to stimulate food intake. It has been suggested that in pancreatic islets, GABA serves as a functional regulator of pancreatic hormone release. Conflicting results have been reported concerning the potential impact of GAD2 variation on estimates of energy metabolism. The aim of this study was to elucidate potential associations between the GAD2-243A-->G polymorphism and levels of body mass index (BMI) and estimates of glycaemia.
Using high-throughput chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, the GAD2-243A-->G (rs2236418) polymorphism was genotyped in a population-based sample (Inter99) of 5857 middle-aged, unrelated Danish White subjects.
The G-allele was associated with modestly lower BMI (P = 0.01). In a case-control study of obesity, the G-allele frequency in 2582 participants with BMI < 25 kg/m2 was 19.5% (18.4-20.6) compared with 17.1% (15.5-18.8) in 968 participants having BMI > or = 30 kg/m2 (P = 0.03), odds ratio 0.9 (0.7-1.0). Of the 5857 subjects, GG carriers had lower fasting plasma glucose levels (mmol/l) [AA (n = 3859) 5.6 +/- 0.8; AG (n = 1792) 5.5 +/- 0.8; GG (n = 206) 5.5 +/- 0.8, P = 0.008] and lower 30-min oral glucose tolerance test (OGTT)-related plasma glucose levels (AA 8.7 +/- 1.9; AG 8.6 +/- 1.9; GG 8.6 +/- 2.0, P = 0.04), adjusted for sex, age and BMI. Analysing subjects who were both normoglycaemic and glucose tolerant (n = 4431) GG carriers still had lower fasting plasma glucose concentrations: AA (n = 2895) 5.3 +/- 0.4; AG (n = 1383) 5.3 +/- 0.4; GG (n = 153) 5.2 +/- 0.4 (P = 9.10(-5)).
The present study suggests that the GAD2-243A-->G polymorphism in a population of middle-aged White people associates with a modest reduction in BMI and fasting and OGTT-related plasma glucose levels.
谷氨酸脱羧酶基因(GAD2)编码GAD65,这是一种催化γ-氨基丁酸(GABA)生成的酶,GABA与神经肽Y相互作用以刺激食物摄入。有人提出,在胰岛中,GABA作为胰腺激素释放的功能调节剂。关于GAD2变异对能量代谢估计的潜在影响,已有相互矛盾的报道。本研究的目的是阐明GAD2 - 243A→G多态性与体重指数(BMI)水平及血糖估计值之间的潜在关联。
使用基于芯片的高通量基质辅助激光解吸/电离飞行时间质谱法,对5857名中年、无亲缘关系的丹麦白人受试者的人群样本(Inter99)进行GAD2 - 243A→G(rs2236418)多态性基因分型。
G等位基因与略低的BMI相关(P = 0.01)。在一项肥胖病例对照研究中,2582名BMI < 25 kg/m²参与者的G等位基因频率为19.5%(18.4 - 20.6),而968名BMI≥30 kg/m²参与者的G等位基因频率为17.1%(15.5 - 18.8)(P = 0.03),比值比为0.9(0.7 - 1.0)。在5857名受试者中,GG携带者的空腹血糖水平(mmol/L)较低[AA(n = 3859)5.6±0.8;AG(n = 1792)5.5±0.8;GG(n = 206)5.5±0.8,P = 0.008],30分钟口服葡萄糖耐量试验(OGTT)相关的血糖水平也较低(AA 8.7±1.9;AG 8.6±1.9;GG 8.6±2.0,P = 0.04),经性别、年龄和BMI校正。分析血糖正常且糖耐量正常的受试者(n = 4431),GG携带者的空腹血糖浓度仍较低:AA(n = 2895)5.3±0.4;AG(n = 1383)5.3±0.4;GG(n = 153)5.2±0.4(P = 9.1×10⁻⁵)。
本研究表明,中年白人人群中的GAD2 - 243A→G多态性与BMI适度降低以及空腹和OGTT相关血糖水平降低有关。